It was demonstrated that five intradermal injections of 11 (100 ng‐1 μg) and IFN‐β (10,000 U), given 8 to 10 days after B16‐F10 melanoma tumor cell injection significantly augmented the antitumor effect of IFN‐β in a dose‐dependent manner.88 It should be noted that doses as 11 as low as 100 ng were already sufficient for a statistically significant increase of IFN‐β–mediated antitumor activity against mouse melanoma. The gene discussed is IFNB1; the disease is neoplasm.